Viral Hepatitis Management
During hepatitis infection a high calorie diet is required along with moderate physical activity. The important step in the management of hepatitis is the intake of correct drug with correct dosage and frequency. Hepatitis A does not progress into chronic condition and hence the management requires supportive treatment such as intravenous administration of fluid and nutrition. In most cases hepatitis B results into chronic state and hence drug treatment is mandatory. The drugs used for the treatment of hepatitis B include interferon alpha, Pegylated interferon, Lamivudine, Adefovir dipivoxi, Telbivudine and Tenofovir. The drugs used in the management of hepatitis C include telaprevir, boceprevir, dasabuvir. The treatment of hepatitis D is difficult and lacks specific anti-viral drugs. The management of Hepatitis E includes bed rest along with supplementation of proper nutrition.
Related Conference of Viral Hepatitis Management
15th International Conference on Pulmonary & Respiratory Medicine
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Viral Hepatitis Management Conference Speakers
Recommended Sessions
- Advancement in New Drug Discovery for Treatment of Hepatitis
- Critical Care and Hepatology Nursing
- Epidemiology of Hepatitis
- Hepatitis Care
- Hepatocellular Carcinoma
- Intestinal Rehabilitation
- Liver Cancer
- Liver Diseases Diagnosis
- Liver Fibrosis
- Liver Transplantation and Surgery
- Molecular Biology of Hepatitis A, B, C, D and E Viruses
- Pancreatic Diseases
- Pathophysiology of Hepatitis
- Pediatric Gastroenterology, Hepatology and Nutrition
- Pregnancy and Liver Diseases
- Recent Advances in the Viral Hepatitis C Treatment
- Types of Hepatitis
- Viral Hepatitis Management
Related Journals
Are you interested in
- Advancements in Pulmonary Diagnostics - Respiratory 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Cardio Pulmonary Disorders - Respiratory 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic Obstructive Pulmonary Disease - Respiratory 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and Asthma - Respiratory 2024 (France)
- COVID-19 and Respiratory System - Respiratory 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Idiopathic Pulmonary Fibrosis - Respiratory 2024 (France)
- Interstitial Lung Disease - Respiratory 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung Cancer - Respiratory 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung Transplantation - Respiratory 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Obstructive Sleep Apnea - Respiratory 2024 (France)
- Occupational Lung Diseases - Respiratory 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pneumonia - Respiratory 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary diseases: Treatment, Diagnosis and therapies - Respiratory 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary Hypertension - Respiratory 2024 (France)
- Pulmonary Rehabilitation - Respiratory 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Tuberculosis - Respiratory 2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)